| Literature DB >> 10579801 |
S Gupta1, M Srivastava, N Ahmad, D G Bostwick, H Mukhtar.
Abstract
Aberrant or increased expression of cyclooxygenase (COX)-2 has been implicated in the pathogenesis of many diseases including carcinogenesis. COX-2 has been shown to be over-expressed in some human cancers. Employing semi-quantitative reverse transcription-PCR, immunoblotting, and immunohistochemistry we assessed COX-2 expression in samples of pair-matched benign and cancer tissue obtained from the same prostate cancer patient. Mean levels of COX-2 mRNA were 3.4-fold higher in prostate cancer tissue (n = 12) compared with the paired benign tissue. The immunoblot analysis demonstrated that as compared to benign tissue COX-2 protein was over-expressed in 10 of 12 samples examined. Immunohistochemical analysis also verified COX-2 over-expression in cancer than in benign tissue. To our knowledge, this is the first in vivo study showing an over-expression of COX-2 in prostate cancer. These data suggest that COX-2 inhibitors may be useful for prevention or therapy of prostate cancer in humans. Copyright 2000 Wiley-Liss, Inc.Entities:
Mesh:
Substances:
Year: 2000 PMID: 10579801 DOI: 10.1002/(sici)1097-0045(20000101)42:1<73::aid-pros9>3.0.co;2-g
Source DB: PubMed Journal: Prostate ISSN: 0270-4137 Impact factor: 4.104